Caution/Monitor.atazanaviratazanavir will increase the level or effect of fluticasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inhibitors may increase fluticasone systemic exposureatazanavir increases levels of salmeterol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Potential for increased toxicity. Use alternatives if available. Increased risk of systemic effects.atenololatenolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.atenolol decreases effects of salmeterol by pharmacodynamic antagonism. Use Caution/Monitor.carbamazepinecarbamazepine will decrease the level or effect of fluticasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.atomoxetinesalmeterol, atomoxetine. Other (see comment). Use Caution/Monitor. Comment: Exercise caution if beta-agonists and atomoxetine are coadministered. Interaction may be less likely with inhaled beta-agonists versus those given systemically. .azelastineazelastine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.belladonna and opiumbelladonna and opium increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.bendroflumethiazidesalmeterol and bendroflumethiazide both decrease serum potassium. Use Caution/Monitor.benperidolbenperidol increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.benzphetaminesalmeterol and benzphetamine both decrease sedation. Use Caution/Monitor.salmeterol and benzphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.betaxololbetaxolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.betaxolol decreases effects of salmeterol by pharmacodynamic antagonism. Use Caution/Monitor.bisoprololbisoprolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.bisoprolol decreases effects of salmeterol by pharmacodynamic antagonism. Use Caution/Monitor.brompheniraminebrompheniramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.bumetanidesalmeterol and bumetanide both decrease serum potassium. Use Caution/Monitor.buprenorphine buccalbuprenorphine buccal increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.butabarbitalbutabarbital increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.butalbitalbutalbital increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.butorphanolbutorphanol increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.caffeinesalmeterol and caffeine both decrease sedation. Use Caution/Monitor.carbenoxolonesalmeterol and carbenoxolone both decrease serum potassium. Use Caution/Monitor.carbinoxaminecarbinoxamine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.carvedilolcarvedilol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.carvedilol decreases effects of salmeterol by pharmacodynamic antagonism. Use Caution/Monitor.celecoxibcelecoxib increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.celiprololceliprolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.celiprolol decreases effects of salmeterol by pharmacodynamic antagonism. Use Caution/Monitor.cenobamatecenobamate will decrease the level or effect of fluticasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.cenobamate will decrease the level or effect of salmeterol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.ceritinibceritinib will increase the level or effect of fluticasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.chloral hydratechloral hydrate increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorothiazidesalmeterol and chlorothiazide both decrease serum potassium. Use Caution/Monitor.chlorpheniraminechlorpheniramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazinechlorpromazine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorthalidonesalmeterol and chlorthalidone both decrease serum potassium. Use Caution/Monitor.choline magnesium trisalicylatecholine magnesium trisalicylate increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor. .cinnarizinecinnarizine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.citalopramcitalopram and salmeterol both increase QTc interval. Use Caution/Monitor.clarithromycinclarithromycin and salmeterol both increase QTc interval. Use Caution/Monitor.clarithromycin will increase the level or effect of fluticasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inhibitors may increase fluticasone systemic exposureclarithromycin will increase the level or effect of salmeterol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.clemastineclemastine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.cobicistatcobicistat increases levels of fluticasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.clomipramineclomipramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clonazepamclonazepam increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clorazepateclorazepate increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clozapineclozapine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.clozapine and salmeterol both increase QTc interval. Use Caution/Monitor.codeinecodeine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.conivaptanconivaptan will increase the level or effect of salmeterol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.conivaptan will increase the level or effect of fluticasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inhibitors may increase fluticasone systemic exposurecrizotinibcrizotinib and salmeterol both increase QTc interval. Use Caution/Monitor.darunavirdarunavir will increase the level or effect of fluticasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inhibitors may increase fluticasone systemic exposurecyclizinecyclizine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.cyclopenthiazidesalmeterol and cyclopenthiazide both decrease serum potassium. Use Caution/Monitor.cyproheptadinecyproheptadine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dabrafenibdabrafenib will decrease the level or effect of salmeterol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.dasatinibdasatinib and salmeterol both increase QTc interval. Use Caution/Monitor.deflazacortsalmeterol and deflazacort both decrease serum potassium. Use Caution/Monitor.degarelixdegarelix and salmeterol both increase QTc interval. Use Caution/Monitor.desipraminedesipramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.deutetrabenazinedeutetrabenazine and salmeterol both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexchlorpheniraminedexchlorpheniramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexfenfluraminesalmeterol and dexfenfluramine both decrease sedation. Use Caution/Monitor.salmeterol and dexfenfluramine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.dexmedetomidinedexmedetomidine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexmethylphenidatesalmeterol and dexmethylphenidate both decrease sedation. Use Caution/Monitor.salmeterol and dexmethylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.dextroamphetaminesalmeterol and dextroamphetamine both decrease sedation. Use Caution/Monitor.salmeterol and dextroamphetamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.dextromoramidedextromoramide increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.diamorphinediamorphine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dichlorphenamidedichlorphenamide and salmeterol both decrease serum potassium. Use Caution/Monitor.diclofenacdiclofenac increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.diethylpropionsalmeterol and diethylpropion both decrease sedation. Use Caution/Monitor.salmeterol and diethylpropion both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.difenoxin hcldifenoxin hcl increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.diflunisaldiflunisal increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.digoxindigoxin increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.dimenhydrinatedimenhydrinate increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.diphenhydraminediphenhydramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.diphenoxylate hcldiphenoxylate hcl increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dipipanonedipipanone increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dobutaminedobutamine and salmeterol both decrease serum potassium. Use Caution/Monitor.dobutamine and salmeterol both decrease sedation. Use Caution/Monitor.dobutamine and salmeterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.dolasetrondolasetron and salmeterol both increase QTc interval. Use Caution/Monitor.donepezildonepezil and salmeterol both increase QTc interval. Use Caution/Monitor.dopaminesalmeterol and dopamine both decrease sedation. Use Caution/Monitor.salmeterol and dopamine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.dopexaminedopexamine and salmeterol both decrease serum potassium. Use Caution/Monitor.dopexamine and salmeterol both decrease sedation. Use Caution/Monitor.dopexamine and salmeterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.dopexamine, salmeterol. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.doxepindoxepin increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.doxepin and salmeterol both increase QTc interval. Use Caution/Monitor.droperidoldroperidol increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.drospirenonedrospirenone increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Modify Therapy/Monitor Closely.duvelisibduvelisib will increase the level or effect of salmeterol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.efavirenzefavirenz and salmeterol both increase QTc interval. Use Caution/Monitor.elagolixelagolix decreases levels of salmeterol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.elvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF will increase the level or effect of fluticasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inhibitors may increase fluticasone systemic exposureelvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of salmeterol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.encorafenibencorafenib, salmeterol. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.encorafenib and salmeterol both increase QTc interval. Use Caution/Monitor.fedratinibfedratinib will increase the level or effect of fluticasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.entrectinibentrectinib and salmeterol both increase QTc interval. Use Caution/Monitor.ephedrineephedrine and salmeterol both decrease serum potassium. Use Caution/Monitor.ephedrine and salmeterol both decrease sedation. Use Caution/Monitor.ephedrine and salmeterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.epinephrineepinephrine and salmeterol both decrease serum potassium. Use Caution/Monitor.epinephrine and salmeterol both decrease sedation. Use Caution/Monitor.epinephrine and salmeterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.epinephrine racemicepinephrine racemic and salmeterol both decrease serum potassium. Use Caution/Monitor.epinephrine racemic and salmeterol both decrease sedation. Use Caution/Monitor.epinephrine racemic and salmeterol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.eribulineribulin and salmeterol both increase QTc interval. Use Caution/Monitor.esmololesmolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.esmolol decreases effects of salmeterol by pharmacodynamic antagonism. Use Caution/Monitor.estazolamestazolam increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ethacrynic acidsalmeterol and ethacrynic acid both decrease serum potassium. Use Caution/Monitor.ethanolethanol increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.etodolacetodolac increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.fedratinibfedratinib will increase the level or effect of salmeterol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.fenfluraminesalmeterol and fenfluramine both decrease sedation. Use Caution/Monitor.salmeterol and fenfluramine both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.fenoprofenfenoprofen increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.fingolimodfingolimod and salmeterol both increase QTc interval. Use Caution/Monitor.fluoxetinefluoxetine and salmeterol both increase QTc interval. Modify Therapy/Monitor Closely. Fluoxetine prolongs the QT interval; the prescribing information for fluoxetine recommends avoiding concurrent use of other drugs that may prolong the QT interval; risk may be increased with higher doses and/or when associated with hypokalemia; drugs that prolong the QTc interval may potentiate the effects of beta2 agonists on the cardiovascular systemfluphenazinefluphenazine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use